PMAM
AIMT

Penn Mutual Asset Management’s Aimmune Therapeutics AIMT Stock Holding History

Penn Mutual Asset Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-158,783
Closed -$5.47M – 77
2020
Q3 		$5.47M Buy
+158,783
New +$3.38M 7.72% 3

Penn Mutual Asset Management's AIMT Position: Q4 2020 in Review

Penn Mutual Asset Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 158,783 shares — an estimated $5.47M sold.

Penn Mutual Asset Management first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $5.47M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Penn Mutual Asset Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Penn Mutual Asset Management sold 158,783 Aimmune Therapeutics shares in Q4 2020, an estimated $5.47M.
  • Penn Mutual Asset Management first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
  • Penn Mutual Asset Management's Aimmune Therapeutics position peaked at $5.47M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Penn Mutual Asset Management's 13F filing for Q4 2020, filed 9 Feb 2021.